Press
Metro International Biotech Announces Initial Dosing in the First Cohort of a Phase 1a Clinical Trial of its Novel NAD Booster MIB-725 April 22, 2025
Metro International Biotech, LLC (MetroBiotech), an EdenRoc Sciences company that is developing more effective treatments of age-related diseases, today announced that the first patients in Cohort 1 of its Phase 1a clinical trial of MIB-725 have received their initial doses.
